The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Nanoliposomal Irinotecan for Pancreatic Adenocarcinoma: Second-Line Therapy

Liposome-encapsulated irinotecan combined with 5-fluorouracil and leucovorin for metastatic pancreatic adenocarcinoma after gemcitabine-based therapy progression

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Nanoliposomal Irinotecan for Pancreatic Adenocarcinoma: Second-Line Therapy?

Nanoliposomal irinotecan is pegylated liposome encapsulated topoisomerase I inhibitor with sustained release pharmacokinetics.

Indication is metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.

FDA approval in 2015 followed NAPOLI-1 trial demonstrating overall survival benefit over fluorouracil-leucovorin alone.

NALIRIFOX combination with 5-FU/leucovorin and oxaliplatin from NAPOLI-3 trial expands use to first-line setting.

Liposomal formulation reduces peak drug concentrations potentially improving tolerability over conventional irinotecan.

Symptoms

Severe diarrhea is dose-limiting toxicity requiring aggressive antidiarrheal management with loperamide and supportive care.
Neutropenia and febrile neutropenia represent significant hematologic toxicity requiring growth factor support.
Nausea, vomiting, decreased appetite affect quality of life and nutritional status requiring antiemetic prophylaxis.
Fatigue, weakness, weight loss reflect cancer cachexia and treatment effects requiring supportive care.
Cholinergic syndrome with abdominal cramps, sweating, lacrimation may occur during infusion managed with atropine.

Risk Factors

UGT1A1*28 homozygous (Gilbert syndrome) genotype increases severe neutropenia and diarrhea risk requiring dose modification.
Pre-existing diarrhea, inflammatory bowel disease, recent bowel surgery worsens treatment-related diarrhea.
Hepatic dysfunction with bilirubin elevation requires dose modification per hepatic impairment guidelines.
Performance status decline, advanced age, comorbidities reduce treatment tolerance requiring careful patient selection.
Concurrent strong CYP3A4 inducers reduce irinotecan exposure compromising efficacy.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Metastatic pancreatic adenocarcinoma with disease progression on gemcitabine-based first-line therapy warrants second-line discussion.
  • Adequate performance status, organ function and patient preference for active treatment versus best supportive care guides decisions.
  • Severe diarrhea, dehydration, fever with neutropenia require urgent evaluation and supportive care.
  • UGT1A1 genotype testing may be considered to predict toxicity risk and guide initial dosing.
  • Multidisciplinary care including medical oncology, palliative care, nutrition support, supportive care optimizes outcomes.

Treatment Methods

01
Nanoliposomal irinotecan 70 mg/m2 plus 5-fluorouracil 2400 mg/m2 over 46 hours and leucovorin every 2 weeks.
02
NALIRIFOX regimen adds oxaliplatin to liposomal irinotecan and 5-FU/leucovorin for first-line use.
03
Aggressive antidiarrheal management with loperamide for delayed-onset diarrhea is essential.
04
Granulocyte colony-stimulating factor support for febrile neutropenia prevention may be considered.
05
Comprehensive supportive care including nutrition support, pain management, antiemetic prophylaxis, infection prevention, palliative care integration, treatment of comorbidities, attention to quality of life optimizes outcomes for patients receiving this active second-line or first-line therapy for metastatic pancreatic adenocarcinoma.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.